Office supply giant Staples Inc. announced Wednesday the launch of its own Windows Store app for Staples.com, which provides customers with access to Staples Rewards and features tools that make it easier for small businesses to research and shop for everything they need for their business or home office. Furniture giant Ikea unveiled a proposal Wednesday to expand the warehouse of its Stoughton store after announcing last July that it was cancelling plans to build a second Massachusetts store at Assembly Square in Somerville. Cambridge’s DART Therapeutics Inc., a company focused on developing therapies for Duchenne muscular dystrophy (DMD), is developing a drug candidate obtained from Belgium-based Galapagos NV. Tetraphase Pharmaceuticals Inc. announced Wednesday the pricing of its initial public offering of 10,714,286 shares of common stock at a price to the public of $7.00 per share, less underwriting discounts and commissions. Sun Life Financial Inc. has appointed Jones Lang LaSalle as the exclusive property manager for its US headquarters at One Sun Life Executive Park in Wellesley, where Sun Life has about 1,500 employees. TA Associates, a private equity firm with offices in Boston, said Wednesday that it has completed an investment in Onlineprinters GmbH, one of Europe's largest online printing companies. Terms of the investment were not disclosed. Federal officials Tuesday gave Biogen Idec Inc. new patent protection extending for 15 years for its multiple sclerosis pill Tecfidera, which is awaiting US regulatory approval. The biotechnology company, based in Weston, said the US Patent Office granted a patent covering the 480-milligram daily dosing regimen for dimethyl fumarate, the active ingredient in Tecfridera, through 2028. That is the dosing regimen sought in Biogen Idec’s new drug application, which the Food and Drug Administration is expected to rule on this month. “It’s a very good outcome for Biogen Idec and for multiple sclerosis patients as well,” said Steven Holtzman, the company executive vice president for corporate development. Shares of Biogen Idec edged up 9 cents, or 0.05 percent to $175.61. | | |
No comments:
Post a Comment